<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615220</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-101-TD-301</org_study_id>
    <nct_id>NCT05615220</nct_id>
  </id_info>
  <brief_title>Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults</brief_title>
  <acronym>D1AMOND</acronym>
  <official_title>A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults With Tourette's Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emalex Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emalex Biosciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability&#xD;
      of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's&#xD;
      Disorder (TD). The study includes an open-label period followed by double-blind,&#xD;
      placebo-controlled, randomized withdrawal period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a 28-day Screening period and Baseline visit, eligible subjects will be enrolled&#xD;
      into the open-label Stabilization period comprised of a 4-week Titration phase to achieve a&#xD;
      target steady-state dose of 1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl) followed by an&#xD;
      8-week open-label Maintenance phase. Responders to ecopipam will be randomized to ecopipam&#xD;
      1.8 mg/kg/day (2 mg/kg/day ecopipam HCl) or placebo in a 1:1 fashion and enter the&#xD;
      double-blind Randomized-Withdrawal (R/WD) period at Week 12. During the 12-week R/WD period,&#xD;
      any subject meeting Relapse criteria will be withdrawn from blinded study medication and&#xD;
      complete end of study assessments including safety follow up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a multicenter study which includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Screening up to Week 24</time_frame>
    <description>Clinician-completed rating scale with score ranging from 0 to 50 (0=none to 50=severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Tourette Disorder</condition>
  <arm_group>
    <arm_group_label>1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ecopipam 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 mg tablets (containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively); 1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl) target dose; oral administration daily in evenings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo during R/WD Phase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablets during R/WD period taken orally in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecopipam Hydrochloride</intervention_name>
    <description>Selective dopamine D1 and D5 receptor antagonist</description>
    <arm_group_label>1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl)</arm_group_label>
    <arm_group_label>Placebo during R/WD Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 6 years of age&#xD;
&#xD;
          -  ≥ 18 kg (~ 40 lbs.)&#xD;
&#xD;
          -  TD diagnosis and both motor and vocal tics that cause impairment with normal routines&#xD;
&#xD;
          -  Minimum score of 20 on the YGTSS-R Total Tic Score&#xD;
&#xD;
          -  May not be taking any medications used to treat motor or vocal tics for at least 14&#xD;
             days prior to Baseline.&#xD;
&#xD;
          -  Effective contraception during the study and 30 days after last study dose for&#xD;
             sexually active subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to ecopipam&#xD;
&#xD;
          -  Certain mood or psychiatric disorders (i.e., dementia, bipolar disorder,&#xD;
             schizophrenia, major depressive disorder)&#xD;
&#xD;
          -  Unstable unstable medical illness or clinically significant lab abnormalities&#xD;
&#xD;
          -  Risk of suicide&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Moderate to severe renal insufficiency&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
&#xD;
          -  Unstable doses for drugs to treat anxiety, depression, Attention Deficit Hyperactivity&#xD;
             Disorder&#xD;
&#xD;
          -  Certain medications that would lead to drug interactions&#xD;
&#xD;
          -  Recent behavioral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meredith M Miller</last_name>
    <phone>773 343 0671</phone>
    <email>mmiller@emalexbiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David JB Kim</last_name>
    <phone>312 847 1342</phone>
    <email>dkim@emalexbiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Handal-Thome, MD</last_name>
      <phone>334-836-2000</phone>
      <email>nhandal@harmonex.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Duffy, MD</last_name>
      <phone>714-542-3008</phone>
      <email>JohnGDuffyMD@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bloch, MD</last_name>
      <phone>203-745-9921</phone>
      <email>michael.bloch@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weldon Mauney, MD</last_name>
      <phone>850-934-1299</phone>
      <email>wmauney@nwflcrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research in Miami Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013-3834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Sanchez Cazau</last_name>
      <phone>305-889-6670</phone>
      <email>dcazau@researchinmiami.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APG Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morteza Nadjafi, MD</last_name>
      <phone>407-921-2448</phone>
      <email>MORIAPG@GMAIL.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology, PA</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Davis, MD</last_name>
      <phone>407-293-1122</phone>
      <email>rgdavis@pediaticneurologypa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chicago Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Jaffe, MD</last_name>
      <phone>773-282-9845</phone>
      <email>monika.jaffe@chicagoresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1447</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Grant, MD</last_name>
      <phone>773-834-1325</phone>
      <email>jongrant@uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Josephson-Wallack-Munshower Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Ridel, MD</last_name>
      <phone>317-537-6058</phone>
      <email>ridelkands@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Geller, MD</last_name>
      <phone>617-724-5141</phone>
      <email>dan.geller@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Clinical Research Institute PC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajaprabhakaran Rajarethinam, MD</last_name>
      <phone>734-834-8954</phone>
      <email>rpmmc@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Medicine Group</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302-1952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Jackson, MD</last_name>
      <phone>248-290-5400</phone>
      <email>richardjackson2000@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Duffy, MD</last_name>
      <phone>402-817-2235</phone>
      <email>drduffy@alivation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivkumar S Hatti, MD</last_name>
      <phone>610-891-9024</phone>
      <email>shatti@surburanresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Lehman, MD</last_name>
      <phone>843-518-5642</phone>
      <email>rebecca.lehman@uscmed.sc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Access Clinical Trials, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-6502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James (Alan) Fry, MD</last_name>
      <phone>615-320-6076</phone>
      <email>drafry@accessclintrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Nick Russo, MD</last_name>
      <phone>713-500-5511</phone>
      <email>Sam.N.Russo@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Road Runner Research Ltd.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249-3539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Tomasovic</last_name>
      <phone>210-949-0505</phone>
      <email>jtomasovic@rrresearchsa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedar Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reid Robison, MD</last_name>
      <phone>801-369-8989</phone>
      <email>reid.robinson@numinus.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Knutson, MD</last_name>
      <email>drjames.knutson@ccrtrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Kids Clinic Inc</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1Z 0M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohail Khattak, MD</last_name>
      <phone>905 6834440</phone>
      <email>skhattak@kidsclinic.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

